Search for Clinical Trial Results
Autoimmune Hepatitis - 30 Studies Found
Status | Study |
Not yet recruiting |
Study Name: Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis Condition: Autoimmune Diseases Date: 2016-02-28 Interventions: Biological: Regulatory T cells Regulatory t cells will be injected back to autoimmune hepatitis patients |
Not yet recruiting |
Study Name: Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis Condition: Hepatitis, Autoimmune Date: 2016-08-09 Interventions:
|
Recruiting |
Study Name: Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Condition:
|
Recruiting |
Study Name: "Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children" Condition:
Interventions: Drug: Metronidazole or Vancomycine Flagyl or Vancomycine x 14 days. |
Not yet recruiting |
Study Name: A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH Condition:
Date: 2016-12-13 Interventions: Biological: Orbcel-C Selected Mesenchymal Stromal Cells derived from human ubmical cord |
Not yet recruiting |
Study Name: Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis Condition:
|
Recruiting |
Study Name: Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Condition:
|
Completed |
Study Name: Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Condition: Primary Sclerosing Cholangitis Date: 2010-03-12 Interventions: Drug: ursodeoxycholic acid (UDCA) Pediatric PSC patients already receiving UDCA therapy will enter a fou |
Recruiting |
Study Name: Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure Condition:
Date: 2012-02-24 Interventions: Drug: Ornithine phenylacetate Up to 36 patients will be en |
RECRUITING |
Study Name: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) Condition: Autoimmune Hepatitis Date: 2024-05-19 Interventions: Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly |